Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Biora Therapeutics ( (BIOR) ) has issued an announcement.
Biora Therapeutics faced potential delisting from Nasdaq due to failing to meet the market value of listed securities (MVLS) and market value of publicly held shares (MVPHS) requirements. Despite receiving an extension to comply with Nasdaq rules, the company must demonstrate compliance by December 9, 2024, to maintain its listing. At a special meeting, stockholders approved key proposals related to issuing common stock and amending the company’s 2018 Plan, reflecting efforts to address compliance challenges.
See more data about BIOR stock on TipRanks’ Stock Analysis page.
